All In Biotech

Drug Trial Radar · NCT06582277

Safety and Immunogenicity of Two Dose Levels of OVX836 Influenza Vaccine as a Booster on Participants Previously Administered With OVX836

Phase 2a, Single Center, Randomized, Double-blind, Study to Evaluate the Immunogenicity and Safety of One Single Administration of OVX836 Influenza Vaccine at Two Dose Levels (180µg or 480μg) Given Intramuscularly (IM), Either as a Booster or a Primary Vaccination in Healthy Adults Previously Administered With OVX836, Influvac Tetra® or Placebo in the OVX836-002 (EudraCT Number: 2019-002939-28) and OVX836-003 (EudraCT Number: 2021-002535-39) Studies.

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

Oct 22, 2024

Primary completion

Jun 2, 2025

Study completion Jun 2, 2025

Sponsor

Lead sponsor
OsivaxIndustry
Sponsor type
Industry
Collaborators
Harmony Clinical Research BVBA; Clinfidence; Inferential; University Hospital, Ghent; KCAS Bio
First posted
Sep 3, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 20 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This phase 2a is designed to evaluate the anamnestic response of a booster dose (either 180 µg or 480 µg) of OVX836 influenza vaccine administered intramuscularly to participants vaccinated three to five years ago in OVX836-002 or OVX836-003 studies. Participants who had received a placebo or Influvac Tetra® in previous studies would serve as controls and would receive the highest dose of OVX836 vaccine (480 µg) as a primary vaccination.

Conditions

  • Vaccine-Preventable Diseases
  • Influenza

Interventions

  • OVX836 shotBiological

    One single administration intramuscularly at Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety evaluation of OVX836 (180µg and 480µg)Time frame: From enrollment to the end of trial at 180 days.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre for Vaccinology (CEVAC) Ghent University Hospital

    Ghent, Belgium

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.